126 results
8-K
EX-99.1
BCLI
Brainstorm Cell Therapeutics, Inc.
28 Jan 22
BrainStorm Cell Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
4:10pm
in the trial using biomarker data and innovative statistical models
Expanded leadership by naming Stacy R. Lindborg, PhD, EVP and Chief Development … response in the trial can be predicted using biomarker data and an innovative statistical model at the 2021 Northeast Amyotrophic Lateral Sclerosis
8-K
EX-99.1
BCLI
Brainstorm Cell Therapeutics, Inc.
22 Nov 23
BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn® in ALS
6:03am
pathways important in neurodegenerative disorders. MSC-NTF cells are harvested from each person with ALS and are manufactured using an innovative … .
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics
8-K
EX-99.1
BCLI
Brainstorm Cell Therapeutics, Inc.
30 Aug 07
Healthcare Industry Leader, Dr. Jonathan C. Javitt, Joins BrainStorm Cell Therapeutics Board of Directors
12:00am
is an innovative enterprise with world-class scientists who have already achieved remarkable preclinical results."
"We are very excited to have Dr. Javitt … process in record time. His innovative guidance will be invaluable to Brainstorm’s management as we move into the clinical phase of our endeavors.”
Dr
8-K
EX-99.1
BCLI
Brainstorm Cell Therapeutics, Inc.
24 Oct 23
BrainStorm Cell Therapeutics Announces Strategic Realignment
7:30am
in neurodegenerative disorders. MSC-NTF cells are harvested from each person with ALS and are manufactured using an innovative and proprietary process … Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating
8-K
EX-99.1
BCLI
Brainstorm Cell Therapeutics, Inc.
20 Dec 23
BrainStorm Issues 2023 Letter to Shareholders
5:04pm
and are manufactured using an innovative and proprietary process to secrete neurotrophic factors to target specific neurodegenerative diseases … of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. BrainStorm holds the rights to clinical development
8-K
EX-99.1
fr8dg
6 Jun 23
Regulation FD Disclosure
8:58am
8-K
EX-99.1
g05zbv
14 Nov 23
BrainStorm Cell Therapeutics Announces Third quarter 2023 Financial Results and Provides Corporate Update
12:00am
8-K
EX-99.1
41nta20wuno v92m
15 Oct 20
BrainStorm Announces Financial Results for the Third Quarter of 2020 and Provides a Corporate Update
7:15am
8-K
EX-99.2
j87kzk uefvb
20 Jul 12
BrainStorm Announces Pricing of Public Offering of Common Stock and Warrants
12:00am
8-K
EX-99.1
5smn 4jmh
11 Apr 24
Other Events
6:10am
8-K
EX-99.1
a40c9 b49
14 Aug 23
BrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
7:21am
8-K
EX-99.1
t73xvxw2qvntd7ie72d
12 Dec 12
BrainStorm Receives 3 Million NIS Grant
12:00am
8-K
EX-99.1
nln4t9yxqkf fyxdnj7
20 Jul 12
BrainStorm Announces Pricing of Public Offering of Common Stock and Warrants
12:00am
8-K
EX-99.1
cw0q7
19 Oct 07
Rami Efrati, Former VP Business Development and Marketing for NICE SYSTEMS' Government Division, Joins BrainStorm As CEO
12:00am
8-K
EX-99.1
jdeqkgknao6s23z
13 Jun 14
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
71vkr2
19 Jul 23
Brainstorm Cell Therapeutics Announces Pricing of $7.5 Million Registered Direct Offering
4:05pm
8-K
EX-99.1
tdpo9
20 Dec 12
BrainStorm and Octane to Develop Revolutionary Bioreactor-Based NurOwn Stem Cells Production Process
12:00am
8-K
EX-99.1
lkixfne8fg59
20 Jun 23
BrainStorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair
5:01pm
8-K
qseqzs0dxsbljd1
3 Sep 20
Departure of Directors or Certain Officers
4:05pm
8-K
EX-99.1
sovru o6nv7t
6 Mar 20
Entry into a Material Definitive Agreement
2:35pm